114 related articles for article (PubMed ID: 38160346)
21. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
22. Identification of 40S ribosomal protein S8 as a novel biomarker for alcohol‑associated hepatocellular carcinoma using weighted gene co‑expression network analysis.
Bi N; Sun Y; Lei S; Zeng Z; Zhang Y; Sun C; Yu C
Oncol Rep; 2020 Aug; 44(2):611-627. PubMed ID: 32627011
[TBL] [Abstract][Full Text] [Related]
23. Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks.
Yu X; Zhang J; Yang R; Li C
Biomed Res Int; 2020; 2020():8579651. PubMed ID: 33299877
[TBL] [Abstract][Full Text] [Related]
24. Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.
Mao JX; Li JJ; Lu XY; Zhong HX; Zhao YY; Zhu LY; Fu H; Ding GS; Teng F; Chen M; Guo WY
Int Immunopharmacol; 2024 Jul; 136():112340. PubMed ID: 38820962
[TBL] [Abstract][Full Text] [Related]
25. Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma.
Xu W; Rao Q; An Y; Li M; Zhang Z
PLoS One; 2018; 13(8):e0202763. PubMed ID: 30138346
[TBL] [Abstract][Full Text] [Related]
26. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
27. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
28. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
29. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes.
Pu M; Wang J; Huang Q; Zhao G; Xia C; Shang R; Zhang Z; Bian Z; Yang X; Tao K
Tumour Biol; 2017 Jul; 39(7):1010428317709127. PubMed ID: 28714366
[TBL] [Abstract][Full Text] [Related]
30. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
32. Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma.
Zhang L; Li Y; Dai Y; Wang D; Wang X; Cao Y; Liu W; Tao Z
Sci Rep; 2021 Sep; 11(1):18875. PubMed ID: 34556750
[TBL] [Abstract][Full Text] [Related]
33. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
[TBL] [Abstract][Full Text] [Related]
34. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
[TBL] [Abstract][Full Text] [Related]
35. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
36. Prognostic model of patients with liver cancer based on tumor stem cell content and immune process.
Kong W; Gao M; Jin Y; Huang W; Huang Z; Xie Z
Aging (Albany NY); 2020 Aug; 12(16):16555-16578. PubMed ID: 32852285
[TBL] [Abstract][Full Text] [Related]
37. Prognostic potential of PRPF3 in hepatocellular carcinoma.
Liu Y; Yang Y; Luo Y; Wang J; Lu X; Yang Z; Yang J
Aging (Albany NY); 2020 Jan; 12(1):912-930. PubMed ID: 31926109
[TBL] [Abstract][Full Text] [Related]
38. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
Guo ZY; Zhu ZT
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
[TBL] [Abstract][Full Text] [Related]
39. PPIH acts as a potential predictive biomarker for patients with common solid tumors.
Ye J; Ying J; Chen H; Wu Z; Huang C; Zhang C; Chen Z; Chen H
BMC Cancer; 2024 Jun; 24(1):681. PubMed ID: 38834966
[TBL] [Abstract][Full Text] [Related]
40. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
